Seres Therapeutics (MCRB) EBT (2016 - 2025)
Historic EBT for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$21.9 million.
- Seres Therapeutics' EBT rose 2335.02% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.2 million, marking a year-over-year increase of 1878.51%. This contributed to the annual value of -$117.3 million for FY2024, which is 3832.36% up from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' EBT is -$21.9 million, which was up 2335.02% from -$24.3 million recorded in Q2 2025.
- Seres Therapeutics' EBT's 5-year high stood at $68.3 million during Q3 2021, with a 5-year trough of -$71.5 million in Q1 2023.
- Its 5-year average for EBT is -$28.4 million, with a median of -$33.4 million in 2024.
- In the last 5 years, Seres Therapeutics' EBT surged by 32286.69% in 2021 and then plummeted by 149549.39% in 2023.
- Quarter analysis of 5 years shows Seres Therapeutics' EBT stood at -$49.7 million in 2021, then surged by 95.58% to -$2.2 million in 2022, then crashed by 1495.49% to -$35.1 million in 2023, then grew by 18.99% to -$28.4 million in 2024, then rose by 23.03% to -$21.9 million in 2025.
- Its last three reported values are -$21.9 million in Q3 2025, -$24.3 million for Q2 2025, and -$26.6 million during Q1 2025.